Shares in Denmark's pharmaceutical giant Novo Nordisk ( NVO -4.99%) were lower by 4% as of 11 a.m. ET today. The move comes as the fallout from the sudden termination of its partnership with telehealth company Hims & Hers continues to escalate.

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss since late April in order to transition patients off compounded drugs, or off-label versions of the medication, according to the news release.

Wegovy is a GLP-1 receptor agonist that acts on key areas of the brain involved in appetite regulation and food intake thereby reducing hunger, improving satiety and reducing cravings for food, eventually inducing weight loss.